US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

BEAM Beam Therapeutics Inc

24.05

-2.26 (-8.59%)

15 Nov 2024 - Cerrado

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/30/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

06/29/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ John Martin Evans III

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Beam Therapeutics (NASDAQ:BEAM)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024

Haga Click aquí para más Gráficas Beam Therapeutics.

Beam Therapeutics (NASDAQ:BEAM)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024

Haga Click aquí para más Gráficas Beam Therapeutics.

Noticias sobre Beam Therapeutics Inc BEAM

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
Martes 12 de Noviembre 2024 (5 días hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 8 de Noviembre 2024 (1 semana hace) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Martes 5 de Noviembre 2024 (2 semanas hace) • Edgar (US Regulatory)

Form 8-K - Current report
Martes 5 de Noviembre 2024 (2 semanas hace) • Edgar (US Regulatory)

Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
Martes 5 de Noviembre 2024 (2 semanas hace) • GlobeNewswire Inc.

Form 8-K - Current report
Martes 5 de Noviembre 2024 (2 semanas hace) • Edgar (US Regulatory)

Form 8-K - Current report
Martes 5 de Noviembre 2024 (2 semanas hace) • Edgar (US Regulatory)

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
Martes 5 de Noviembre 2024 (2 semanas hace) • GlobeNewswire Inc.

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
Martes 29 de Octubre 2024 (3 semanas hace) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Lunes 21 de Octubre 2024 (4 semanas hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 16 de Octubre 2024 (1 mes hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Martes 15 de Octubre 2024 (1 mes hace) • Edgar (US Regulatory)

Más de Beam Therapeutics Inc Artículos de Noticias

American Express

US Dollar vs MXN

Invesco QQQ Trust Series 1

Energy Select Sector SPDR

Euro vs US Dollar

Bank of America

Financial Select Sector

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones